multiple sclerosis drug copaxone (glatiramer acetate) (Teva)
90
Structured Review
Teva
multiple sclerosis drug copaxone (glatiramer acetate)
Multiple Sclerosis Drug Copaxone (Glatiramer Acetate), supplied by Teva, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multiple+sclerosis+drug+copaxone+(glatiramer+acetate)/multiple+sclerosis+drug+copaxone/10__1038_slash_nrd3820-24-15-14
Average 90 stars, based on 1 article reviews
Multiple Sclerosis Drug Copaxone (Glatiramer Acetate), supplied by Teva, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multiple+sclerosis+drug+copaxone+(glatiramer+acetate)/multiple+sclerosis+drug+copaxone/10__1038_slash_nrd3820-24-15-14
Average 90 stars, based on 1 article reviews
multiple sclerosis drug copaxone (glatiramer acetate) - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: US drug makers have imposed big price rises for top selling drugs, study finds. Article Snippet: From 2011 to 2014 drug companies have increased the prices of four of the top 10 drugs sold in the United States by more than 100% and the prices of the remaining six by more than 50%, an analysis by Reuters has found.. According to the news agency, the biggest increase was by AbbVie Inc, which raised the price of arthritis drug Humira (adalimumab) by more than 126%.. The next highest price increases were by Amgen, maker of the arthritis drug Enbrel (etanercept), and Teva Pharmaceuticals, maker of the multiple sclerosis drug Copaxone (glatiramer acetate). Article Title: Patent watch Article Snippet: system encountered a setback on 2 July 2012 because of last-minute proposed changes to the draft legislation.. Currently, a patent issued by the European Patent Office needs to be validated — and litigated — in each individual country that is party to the European Patent Convention.. This can result in greater costs and complexity than in the United States or Japan. Article Title: Biomedical briefing Article Snippet: Stem cell fight over The US Supreme Court rejected a request to hear a case about the legality of federal funding for research involving human embryonic stem cells.. The high court’s decision, announced on 7 January, puts an end to an almost four-year legal challenge that has threatened to derail such work in the country.. The US National Institutes of Health currently spends around $120 million per year on embryonic stem cell research. Article Title: Mythologizing the Story of a Scientific Invention: Constructing the legitimacy of research commercialization Article Snippet: This paper explores the processes through which an organizational story acquires mythological status within an organizational field.. To this end, I analyse a story of a successful case of academic technology transfer that gained mythological status in the field of higher education in Israel: the commercialization of the innovative pharmaceutical drug Copaxone.. I identify three concurrent processes of mythologizing work: organizational storytelling, media diffusion and reconstruction, and field-level retelling and countering. Article Title: News Article Snippet: In a Article Title: Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry. Article Snippet: Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ierp20 Download by: [Cornell University Library] Date: 22 September 2016, At: 23:28 Expert Review of Pharmacoeconomics & Outcomes Research ISSN: 1473-7167 (Print) 1744-8379 (Online) Journal homepage: http://www.tandfonline.com/loi/ierp20 Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry Raphaela Marie Louisa Dierks, Olivier Bruyère, Jean-Yves Reginster & Florent-Frederic Richy To cite this article: Raphaela Marie Louisa Dierks, Olivier Bruyère, Jean-Yves Reginster & Florent-Frederic Richy (2016): Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2016.1239534 To link to this article: http://dx.doi.org/10.1080/14737167.2016.1239534 Accepted author version posted online: 21 Sep 2016.. Submit your article to this journal View related articles View Crossmark data Publisher: Taylor & Francis Journal: Expert Review of Pharmacoeconomics & Outcomes Research DOI: 10.1080/14737167.2016.1239534 Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry Raphaela Marie Louisa Dierks, Olivier Bruyère, Jean-Yves Reginster, Florent-Frederic Richy Université de Liège, Faculty of Medicine, Department of Public Health, Epidemiology and Health Economics, Liège, Belgium.. Corresponding author: Raphaela Dierks, Université de Liège, Faculty of Medicine, Department of Public Health, Epidemiology and Health Economics, CHU Sart-Tilman, 4000 Liège, Belgium. Formulation:Article Title: Form 10-K Article Snippet: .. This strategy has resulted in our collaboration with Eli Lilly and Company for clinical testing of our product to treat autoimmune-mediated diabetes, our agreement with Process/Product Development:Article Title: The New Copycats Article Snippet: GOODBYE, LIPITOR.. Hello, Remicade.. Chemically synthesized drugs like cholesterol-lowering Lipitor, the one-time pharmaceutical sales leader, gained a host of replicas churned out by generic drug companies once patent protection expired. Selection:Article Title: The New Copycats Article Snippet: GOODBYE, LIPITOR.. Hello, Remicade.. Chemically synthesized drugs like cholesterol-lowering Lipitor, the one-time pharmaceutical sales leader, gained a host of replicas churned out by generic drug companies once patent protection expired. |